Travere Therapeutics, Inc. (TVTX)

↓ Download CSV

CIK 0001438533 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated CA
  • Fiscal year ends Dec 31

In fiscal 2025, Travere Therapeutics, Inc. reported revenue of $490.73M, up 110.5% from the prior year. The company ran a net loss, with a net margin of -5.2%. It held $605.19M in total assets against $490.36M in total liabilities.

Key ratios (FY2025)

-12.8%
Operating margin
-5.2%
Net margin
-22.2%
Return on equity
+110.5%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$490.73M$233.18M$145.24M$109.46M$131.84M$198.32M$175.34M$164.25M$154.94M$133.59M
Cost of Revenue$10.34M$7.74M$11.45M$4.42M$3.82M$6.13M$5.23M$5.53M$3.60M$4.55M
Operating Income-$62.82M-$323.83M-$388.14M-$319.81M-$199.43M-$176.16M-$137.36M-$80.04M-$53.79M-$58.21M
Net Income-$25.55M-$321.55M-$111.40M-$278.48M-$180.09M-$169.43M-$146.43M-$102.68M-$59.73M-$47.90M
EPS (Diluted)$-0.29$-4.08$-1.50$-4.37$-3.01$-3.56$-3.46$-2.54$-1.54$-1.29
Total Assets$605.19M$594.12M$788.91M$672.59M$776.63M$607.44M$604.80M$709.16M$520.35M$525.28M
Total Liabilities$490.36M$535.05M$588.10M$629.73M$474.52M$396.23M$383.60M$390.91M$227.21M$217.51M
Shareholders' Equity$114.83M$59.08M$200.81M$42.85M$302.11M$211.21M$221.20M$318.25M$293.13M$307.77M
Cash & Equivalents$93.03M$58.53M$58.18M$61.69M$165.75M$84.77M$62.44M$102.87M$99.39M$41.00M
Operating Cash Flow$37.78M-$237.47M-$280.02M-$186.29M-$14.79M-$42.74M-$58.21M-$24.96M$7.40M-$3.44M
Capital Expenditures$668.0K$191.0K$5.10M$6.77M$195.0K$727.0K$887.0K$1.43M
Shares Outstanding90.92M87.45M75.37M64.29M62.49M52.25M43.09M41.39M39.37M37.91M